title: Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.
abstract: Next generation influenza vaccines containing conserved antigens may enhance immunity against seasonal or pandemic influenza virus strains. Using a plasmid DNA (pDNA)-based vaccine approach, we systematically tested combinations of NP, M1, and M2 antigens derived from consensus sequences for protection against lethal influenza challenge and compared formulations for adjuvanting low pDNA vaccine doses. The highest level of protection at the lowest pDNA doses was provided by Vaxfectin-formulated NP + M2. Vaxfectin adjuvanticity was confirmed with a low dose of HA pDNA. These promising proof-of-concept data support the clinical development of Vaxfectin-formulated pDNA encoding NP + M2 consensus proteins.
authors.affiliation: Vical Incorporated, San Diego, California 92121, USA.
authors.forename: Gretchen S
authors.initials: GS
authors.lastname: Jimenez
authors.forename: Rodrick
authors.initials: R
authors.lastname: Planchon
authors.forename: Qun
authors.initials: Q
authors.lastname: Wei
authors.forename: Denis
authors.initials: D
authors.lastname: Rusalov
authors.forename: Andrew
authors.initials: A
authors.lastname: Geall
authors.forename: Joel
authors.initials: J
authors.lastname: Enas
authors.forename: Peggy
authors.initials: P
authors.lastname: Lalor
authors.forename: Vicky
authors.initials: V
authors.lastname: Leamy
authors.forename: Ruth
authors.initials: R
authors.lastname: Vahle
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Luke
authors.forename: Alain
authors.initials: A
authors.lastname: Rolland
authors.forename: David C
authors.initials: DC
authors.lastname: Kaslow
authors.forename: Larry R
authors.initials: LR
authors.lastname: Smith
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins / Q000235:genetics / Q000276:immunology*; D009976:Orthomyxoviridae Infections / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D016601:RNA-Binding Proteins / Q000235:genetics / Q000276:immunology*; D016019:Survival Analysis; D014611:Vaccination; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D014758:Viral Core Proteins / Q000235:genetics / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins; D000086082:Viroporin Proteins
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D010714:Phosphatidylethanolamines; D016601:RNA-Binding Proteins; D019444:Vaccines, DNA; D014758:Viral Core Proteins; D014763:Viral Matrix Proteins; D014764:Viral Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins; C048842:NP protein, Influenza A virus; C460866:vaxfectin